KPIs & Operating Metrics(New)
Balance Sheet
Accumulated DepreciationAccumulated ExpensesAssetsBuildingsCash & EquivalentsCommon EquityDividends payablesGoodwillGoodwill & IntangiblesIntangiblesLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReal Estate - GrossReal Estate - NetReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Global Medical REIT (GMRE) Common Equity (2016 - 2025)

Historic Common Equity for Global Medical REIT (GMRE) over the last 14 years, with Q3 2025 value amounting to $505.8 million.

  • Global Medical REIT's Common Equity fell 1041.04% to $505.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.8 million, marking a year-over-year decrease of 1041.04%. This contributed to the annual value of $555.9 million for FY2024, which is 823.65% down from last year.
  • Latest data reveals that Global Medical REIT reported Common Equity of $505.8 million as of Q3 2025, which was down 1041.04% from $525.0 million recorded in Q2 2025.
  • Global Medical REIT's Common Equity's 5-year high stood at $664.6 million during Q3 2022, with a 5-year trough of $505.8 million in Q3 2025.
  • Its 5-year average for Common Equity is $604.8 million, with a median of $628.5 million in 2023.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 4394.44% in 2021, then tumbled by 1089.6% in 2024.
  • Over the past 5 years, Global Medical REIT's Common Equity (Quarter) stood at $637.6 million in 2021, then grew by 1.8% to $649.1 million in 2022, then decreased by 6.66% to $605.8 million in 2023, then dropped by 8.24% to $555.9 million in 2024, then fell by 9.01% to $505.8 million in 2025.
  • Its Common Equity stands at $505.8 million for Q3 2025, versus $525.0 million for Q2 2025 and $538.1 million for Q1 2025.